Prof. Marcus Webb MPharm, PhD

Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026

Pulse Biosciences achieves 100% procedural success in atrial fibrillation treatment study with 95 evaluable patients at 6 months, presenting data at Heart Rhythm 2026.

Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026

Acurx presents promising data showing DNA pol IIIC inhibitors effectively treat MRSA infections while preserving gut microbiome, addressing key antibiotic concern.

Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC

Nuvation Bio reports $18.5M Q1 2026 revenue for IBTROZI (taletrectinib) with majority of 200 new patients being TKI-naïve ROS1+ NSCLC cases.

Pharmaceutical Manufacturing Software Market to Reach $7.87 Billion by 2030, Driven by 15.8% CAGR Growth

Pharmaceutical manufacturing software market grows from $3.82B to $4.43B in 2026 with 15.8% CAGR, projected to reach $7.87B by 2030 amid regulatory demands.

Bio-Rad Q1 2026 Results Show IVDR Compliance Costs Impact European Diagnostics Operations

Bio-Rad reports Q1 2026 financial results highlighting increased costs from EU IVDR compliance and product portfolio rationalization in diagnostics market.

COFEPRIS Approval Pathway: Transforming Generic Drugs Market in Mexico

Explore the COFEPRIS approval pathway and its impact on the generic drugs market in Mexico, improving access to vital medications such as Metformin.

Alzheimer's Clinical Trial Failures: Novo Nordisk's Semaglutide Phase 3 Outcome & Market Impact

Novo Nordisk's Semaglutide Phase 3 trial for Alzheimer's has failed, raising concerns about future research and market dynamics in neurodegenerative treatments.

SAHPRA Biosimilars Approval: Trends and Impact on Affordable Medicine Access

This article delves into SAHPRA's recent biosimilars approvals, highlighting trends and their significant role in enhancing access to affordable medications.

Saudi Arabian Pharmaceutical Market: Impact of SFDA Expedited Drug Approvals

This article examines how the SFDA's expedited drug approvals are transforming the Saudi Arabian pharmaceutical landscape, improving access to essential treatments.

Small Molecule API Market Projected to Reach $202.53 Billion by 2036 as Generic Drug Demand Surges

Small molecule API market set to hit $202.53 billion by 2036, driven by generic drug demand and oncology pipeline expansion across global markets.

Novo Nordisk Presents New Wegovy Data for Women with Obesity at European Congress on Obesity 2026

Novo Nordisk unveils new clinical data on Wegovy for women with obesity and next-generation weight loss treatments at European Congress on Obesity in Istanbul.

HIV Clinical Trials Africa: IMPALA Trial Validates CAB/RPV LA Efficacy

The IMPALA trial confirms the efficacy of CAB/RPV LA in treating HIV, showcasing its potential to improve patient care in Africa.

Elanco's Negasunt and Tanidil Receive FDA Emergency Authorization for New World Screwworm Treatment in Livestock

FDA grants emergency use authorization for Elanco's Negasunt Powder and Tanidil to combat New World screwworm in livestock, preparing U.S. veterinarians.

NMPA Approval ADCs Lung Cancer: Trends & Clinical Insights 2025

This article delves into the latest NMPA-approved antibody-drug conjugates (ADCs) for lung cancer, examining trends and clinical insights shaping 2025.

FDA Approval KRAS G12C NSCLC: Sotorasib & Adagrasib Insights

Explore the latest insights on FDA-approved Sotorasib and Adagrasib for treating KRAS G12C NSCLC, transforming lung cancer therapy.

Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline

Oncotelic Therapeutics provides corporate update on strategic partnerships to advance clinical-stage cancer treatments and expand market reach.

African Medicines Agency: Progress in Harmonizing Regulatory Standards Across Africa

The African Medicines Agency is making strides in harmonizing regulatory standards, enhancing the safety and efficacy of medicines like antimalarials across the continent.

Cumberland Pharmaceuticals Announces Strategic Integration with Apotex in Major Commercial Partnership Deal

Cumberland Pharmaceuticals (CPIX) enters strategic agreement with Apotex to integrate commercial operations, marking significant shift in specialty pharma landscape.

SamaCare Launches Industry-First Prior Authorization Performance Benchmarks for Medical Benefit Drugs

SamaCare introduces first-of-its-kind benchmarks tracking prior authorization approval rates and time to therapy across specialty practices nationwide.

Pet Service Holding Reports 2025 Annual Results Amid European Veterinary Regulatory Changes

Pet Service Holding NV announces 2025 annual results showing strategic transition while navigating evolving European veterinary medicine regulations.

Roche's Gazyva Receives FDA Acceptance for Lupus Treatment Following Positive Phase III Trial Results

FDA accepts Roche's supplemental application for Gazyva (obinutuzumab) in systemic lupus erythematosus based on positive ALLEGORY study results.

GRAIL's Galleri Cancer Detection Test Shows Major Results in 174,000-Patient Studies at ASCO 2026

GRAIL presents breakthrough NHS-Galleri and PATHFINDER 2 trial data for multi-cancer early detection test at ASCO 2026, covering 174,000+ participants.

Karyopharm Phase 3 SENTRY Trial Results Selected for ASCO 2026 Late-Breaking Presentation in Myelofibrosis

Karyopharm's Phase 3 SENTRY trial in myelofibrosis earns prestigious late-breaking oral presentation slot at ASCO 2026, signaling potential breakthrough results.

FDA Approval of Viruxa: Market Analysis and Clinical Review for Advanced Melanoma

This article delves into the FDA's recent approval of Viruxa for advanced melanoma, offering a comprehensive market analysis and clinical review.